426 related articles for article (PubMed ID: 1452928)
21. Acute and long-term effects of flosequinan in patients with chronic cardiac failure.
Marchionni N; Moschi G; Di Bari M; Burgisser C; Fumagalli S; Boncinelli L; Tarantini F; Ferrucci L
Am Heart J; 1993 Jul; 126(1):147-54. PubMed ID: 8322657
[TBL] [Abstract][Full Text] [Related]
22. Chronic vasodilator therapy with flosequinan in congestive heart failure.
Haas GJ; Binkley PE; Leier CV
Clin Cardiol; 1990 Jun; 13(6):414-20. PubMed ID: 2188766
[TBL] [Abstract][Full Text] [Related]
23. The effect of flosequinan in patients with heart failure of acute onset complicating acute myocardial infarction.
Schneeweiss A; Wynne RD; Marmor A
Int J Cardiol; 1989 Jul; 24(1):73-6. PubMed ID: 2668206
[TBL] [Abstract][Full Text] [Related]
24. Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects.
Cowley AJ; Wynne RD; Stainer K; Fullwood L; Rowley JM; Hampton JR
BMJ; 1988 Jul; 297(6642):169-73. PubMed ID: 3044507
[TBL] [Abstract][Full Text] [Related]
25. RO13-6438, a new inotrope-vasodilator: systemic and coronary hemodynamic effects in congestive heart failure.
Daly PA; Chatterjee K; Viquerat CE; Parmley WW; Curran D; Scheinbaum M; Anderson S
Am J Cardiol; 1985 Jun; 55(13 Pt 1):1539-44. PubMed ID: 4003296
[TBL] [Abstract][Full Text] [Related]
26. Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: experience from trials of flosequinan.
Massie BM; Shah NB; Pitt B; Packer M
Am Heart J; 1996 Jul; 132(1 Pt 1):130-6. PubMed ID: 8701855
[TBL] [Abstract][Full Text] [Related]
27. Hemodynamic action of nicorandil in chronic congestive heart failure.
Solal AC; Jaeger P; Bouthier J; Juliard JM; Dahan M; Gourgon R
Am J Cardiol; 1989 Jun; 63(21):44J-48J. PubMed ID: 2525325
[TBL] [Abstract][Full Text] [Related]
28. Acute effects of oral pirbuterol on myocardial oxygen metabolism and systemic hemodynamics in chronic congestive heart failure.
Rude RE; Turi Z; Brown EJ; Lorell BH; Colucci WS; Mudge GH; Taylor CR; Grossman W
Circulation; 1981 Jul; 64(1):139-45. PubMed ID: 7237712
[TBL] [Abstract][Full Text] [Related]
29. Systemic and coronary hemodynamic and neurohumoral effects of levodopa in chronic congestive heart failure.
De Marco T; Daly PA; Chatterjee K
Am J Cardiol; 1988 Dec; 62(17):1228-33. PubMed ID: 2904216
[TBL] [Abstract][Full Text] [Related]
30. Hemodynamic and neurohumoral responses to intravenous nicorandil in congestive heart failure in humans.
Giles TD; Pina IL; Quiroz AC; Roffidal L; Zaleski R; Porter RS; Karalis DG; Mohrland JS; Wolf DL; Hearron AE
J Cardiovasc Pharmacol; 1992 Oct; 20(4):572-8. PubMed ID: 1280713
[TBL] [Abstract][Full Text] [Related]
31. Enalaprilat, a new parenteral angiotensin-converting enzyme inhibitor: rapid changes in systemic and coronary hemodynamics and humoral profile in chronic heart failure.
De Marco T; Daly PA; Liu M; Kayser S; Parmley WW; Chatterjee K
J Am Coll Cardiol; 1987 May; 9(5):1131-8. PubMed ID: 3033043
[TBL] [Abstract][Full Text] [Related]
32. Hemodynamic effects of vasodilators and long-term response in heart failure.
Franciosa JA; Dunkman WB; Leddy CL
J Am Coll Cardiol; 1984 Jun; 3(6):1521-30. PubMed ID: 6325522
[TBL] [Abstract][Full Text] [Related]
33. Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failure.
Burstein S; Semigran MJ; Dec GW; Boucher CA; Fifer MA
J Am Coll Cardiol; 1992 Oct; 20(4):822-9. PubMed ID: 1527293
[TBL] [Abstract][Full Text] [Related]
34. Hemodynamic and metabolic effects of vasodilator therapy for heart failure in acute myocardial infarction.
Kodama K; Koretsune Y; Nanto S; Taniura K
Jpn Circ J; 1984 Apr; 48(4):380-7. PubMed ID: 6425527
[TBL] [Abstract][Full Text] [Related]
35. Acute hemodynamic effects of nitrendipine in chronic congestive heart failure.
Olivari MT; Levine TB; Cohn JN
J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S1002-5. PubMed ID: 6085356
[TBL] [Abstract][Full Text] [Related]
36. Intravenous and oral prenalterol in congestive heart failure. Effects on systemic and coronary hemodynamics and myocardial catecholamine balance.
Wahr DW; Swedberg K; Rabbino M; Hoyle MJ; Curran D; Parmley WW; Chatterjee K
Am J Med; 1984 Jun; 76(6):999-1005. PubMed ID: 6731471
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of flosequinan, given over 3 days, evaluated by continuous hemodynamic monitoring.
Schneeweiss A; Plich M; Green T; Wynne RD; Marmor A
Cardiology; 1989; 76(3):201-5. PubMed ID: 2776141
[TBL] [Abstract][Full Text] [Related]
38. Usefulness and limitations of vasodilator therapy in the treatment of pump failure complicated by acute myocardial infarction.
Saito M; Hiramori K; Haze K; Sumiyoshi T; Fukami K; Goto Y
Jpn Circ J; 1984 Apr; 48(4):340-9. PubMed ID: 6716634
[TBL] [Abstract][Full Text] [Related]
39. Effects of balanced vasodilator, flosequinan, on aortic impedance in failing heart.
Yano M; Kohno M; Yamamoto T; Hisaoka T; Tanigawa T; Ono K; Lee B; Konishi M; Matsuzaki M
J Cardiovasc Pharmacol; 1998 Sep; 32(3):466-70. PubMed ID: 9733361
[TBL] [Abstract][Full Text] [Related]
40. Positive inotropic and hemodynamic properties of flosequinan, a new vasodilator, and a sulfone metabolite.
Falotico R; Haertlein BJ; Lakas-Weiss CS; Salata JJ; Tobia AJ
J Cardiovasc Pharmacol; 1989 Sep; 14(3):412-8. PubMed ID: 2476620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
